The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an "undruggable" target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transformation, improved KRAS-targeted drugs, and immunological approaches that aim at yielding immune responses against KRAS neoantigens have sparked a race for approved therapies. Few treatments are available for KRAS mutant NSCLC patients, and several approaches are being tested in clinicals trials to fill this void. Here, we review promising therapeutics tested for KRAS mutant NSCLC. © 2020 The Author(s).

Citation

Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, Arin Nam, Martin Sattler. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell reports. Medicine. 2021 Jan 19;2(1):100186

Mesh Tags

Substances

PMID: 33521700

search → result